Publisher Logo
sales@marketinsights.report
Report banner
Oncolytic Virotherapy Market
Updated On

Jan 28 2025

Total Pages

125

Oncolytic Virotherapy Market Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

Oncolytic Virotherapy Market by Virus Type (Genetically engineered oncolytic viruses, Oncolytic wild-type viruses), by Application (Solid tumors, Melanoma), by End-user (Hospitals, Specialty clinics, Cancer research institutes), by North America (U.S., Canada), by Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe), by Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), by Latin America (Brazil, Mexico, Rest of Latin America), by Middle East and Africa (South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa) Forecast 2025-2033

Publisher Logo

Oncolytic Virotherapy Market Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

Key Insights

The size of the Oncolytic Virotherapy Market was valued at USD 20.1 Million in 2024 and is projected to reach USD 106.52 Million by 2033, with an expected CAGR of 26.9% during the forecast period. The Oncolytic Virotherapy Market centers on the creation and application of oncolytic viruses, which are engineered viruses crafted to specifically attack and eliminate cancer cells while leaving healthy tissue unharmed. These treatments utilize the inherent capacity of specific viruses to invade and multiply inside tumor cells, resulting in the death of tumor cells and a boosted immune reaction. Oncolytic virotherapy is a developing field in cancer treatment and is under investigation for several types of cancer, such as melanoma, breast cancer, glioblastoma, and prostate cancer. The market is propelled by the rising demand for advanced cancer treatments, particularly those that have fewer side effects than conventional methods such as chemotherapy and radiation. Progress in genetic engineering, viral vector technologies, and immune checkpoint modulation is improving the effectiveness and safety of these treatments. Furthermore, continuous clinical studies and regulatory backing for oncolytic virus therapies are driving market expansion. With advancements in the field, the Oncolytic Virotherapy Market is anticipated to grow, providing fresh hope for individuals facing challenging cancers and possibly transforming cancer treatment approaches.

Oncolytic Virotherapy Market Research Report - Market Size, Growth & Forecast

Oncolytic Virotherapy Market Concentration & Characteristics

The market is moderately concentrated, with a few major players holding a significant market share. These players are focused on developing and commercializing innovative oncolytic virus therapies. Partnerships and collaborations, along with M&A activities, are prevalent in the market, as companies seek to expand their pipelines and gain a competitive edge. Stringent regulations, especially in the US and EU, impact market dynamics, ensuring patient safety and data integrity.

Oncolytic Virotherapy Market Trends

The market is witnessing a shift towards genetically engineered oncolytic viruses, which offer greater control over virus replication, tumor specificity, and immune stimulation. Combination therapies, involving oncolytic viruses and immune checkpoint inhibitors, are gaining traction, as they enhance antitumor efficacy. Nanotechnology-based approaches are being explored to improve virus delivery and targeting, thereby enhancing therapeutic outcomes.

Oncolytic Virotherapy Market Growth

Key Region or Country & Segment to Dominate the Market

North America currently dominates the market, driven by high cancer incidence rates and advanced healthcare infrastructure. The US is the leading contributor to the region's market share, owing to significant investments in research and development and a favorable regulatory environment. Asia Pacific is expected to be the fastest-growing region, with China and India emerging as key markets due to rising cancer prevalence and increasing healthcare expenditure.

Oncolytic wild-type viruses are expected to gain prominence in the market, as they have demonstrated promising antitumor activity in clinical trials. Solid tumors, particularly breast, prostate, lung, and glioblastoma, are expected to remain major application areas for oncolytic virotherapies. Hospitals and specialty clinics are the dominant end-users, as they provide specialized care and advanced facilities for cancer treatment.

Oncolytic Virotherapy Market Product Insights Report Coverage & Deliverables

This report provides comprehensive insights into the Oncolytic Virotherapy Market, including market size, market share, and growth trends. It covers various market segments, including virus type, application, and end-user. The report analyzes key regional markets and provides insights into industry developments, driving forces, challenges, restraints, and emerging trends.

Oncolytic Virotherapy Market Analysis

The global Oncolytic Virotherapy Market is expected to maintain a steady growth trajectory, influenced by factors such as healthcare infrastructure development, rising awareness of cancer immunotherapy, and technological advancements. The report provides a comprehensive analysis of market size, market share, and growth dynamics across different segments.

Oncolytic Virotherapy Market Regional Insights

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East and Africa

Driving Forces: What's Propelling the Oncolytic Virotherapy Market

  • Rising prevalence of cancer worldwide
  • Growing demand for personalized cancer treatment
  • Favorable regulatory framework in key markets
  • Technological advancements in virus engineering

Challenges and Restraints in Oncolytic Virotherapy Market

  • Safety concerns associated with oncolytic viruses
  • Limited efficacy against certain tumor types
  • Complex manufacturing process
  • Reimbursement challenges

Emerging Trends in Oncolytic Virotherapy Market

  • Development of next-generation oncolytic viruses with enhanced tumor targeting
  • Combination therapies with immune checkpoint inhibitors
  • Nanotechnology-based approaches for improved virus delivery
  • Personalized medicine approaches to optimize treatment outcomes

Oncolytic Virotherapy Industry News

  • January 2023: Theriva Biologics announced that the U.S. FDA has granted an orphan drug designation to VCN-01, an oncolytic adenovirus for the treatment of patients with pancreatic cancer.
  • October 2021: Virogn Biotech announced that the U.S. FDA has granted an orphan drug designation to its Class I innovative oncolytic virus product, VG161, for the treatment of Intrahepatic Cholangiocarcinoma.

Leading Players in the Oncolytic Virotherapy Market 

Oncolytic Virotherapy Market Segmentation

  • 1. Virus Type
    • 1.1. Genetically engineered oncolytic viruses
      • 1.1.1. Adenovirus
      • 1.1.2. Herpes simplex virus
      • 1.1.3. Vaccinia virus
    • 1.2. Oncolytic wild-type viruses
      • 1.2.1. Reovirus
      • 1.2.2. Vesicular stomatitis virus
      • 1.2.3. Newcastle disease virus
  • 2. Application
    • 2.1. Solid tumors
      • 2.1.1. Breast cancer
      • 2.1.2. Prostate cancer
      • 2.1.3. Lung cancer
      • 2.1.4. Glioblastoma
    • 2.2. Melanoma
      • 2.2.1. Leukemia
      • 2.2.2. Lymphoma
      • 2.2.3. Myeloma
      • 2.2.4. Hematological malignancies
  • 3. End-user
    • 3.1. Hospitals
    • 3.2. Specialty clinics
    • 3.3. Cancer research institutes

Oncolytic Virotherapy Market Segmentation By Geography

  • 1. North America
    • 1.1. U.S.
    • 1.2. Canada
  • 2. Europe
    • 2.1. Germany
    • 2.2. UK
    • 2.3. France
    • 2.4. Spain
    • 2.5. Italy
    • 2.6. Netherlands
    • 2.7. Rest of Europe
  • 3. Asia Pacific
    • 3.1. China
    • 3.2. Japan
    • 3.3. India
    • 3.4. Australia
    • 3.5. South Korea
    • 3.6. Rest of Asia Pacific
  • 4. Latin America
    • 4.1. Brazil
    • 4.2. Mexico
    • 4.3. Rest of Latin America
  • 5. Middle East and Africa
    • 5.1. South Africa
    • 5.2. Saudi Arabia
    • 5.3. UAE
    • 5.4. Rest of Middle East and Africa

Oncolytic Virotherapy Market Regional Share

Oncolytic Virotherapy Market REPORT HIGHLIGHTS

AspectsDetails
Study Period 2019-2033
Base Year 2024
Estimated Year 2025
Forecast Period2025-2033
Historical Period2019-2024
Growth RateCAGR of 26.9% from 2019-2033
Segmentation
    • By Virus Type
      • Genetically engineered oncolytic viruses
        • Adenovirus
        • Herpes simplex virus
        • Vaccinia virus
      • Oncolytic wild-type viruses
        • Reovirus
        • Vesicular stomatitis virus
        • Newcastle disease virus
    • By Application
      • Solid tumors
        • Breast cancer
        • Prostate cancer
        • Lung cancer
        • Glioblastoma
      • Melanoma
        • Leukemia
        • Lymphoma
        • Myeloma
        • Hematological malignancies
    • By End-user
      • Hospitals
      • Specialty clinics
      • Cancer research institutes
  • By Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Netherlands
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of Middle East and Africa
Table Of Content
  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Introduction
  3. 3. Market Dynamics
    • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1 Rising incidence of cancer
        • 3.2.2 Growing approvals for oncolytic therapy for treating rare cancers
        • 3.2.3 Increasing investments for developing new oncolytic virotherapies
        • 3.2.4 Growing focus towards combination therapies
      • 3.3. Market Restrains
        • 3.3.1 Issues related to scaling-up of clinical-grade oncolytic viruses
        • 3.3.2 Requirement for high investments in conducting clinical research
      • 3.4. Market Trends
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  5. 5. Global Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 5.1. Market Analysis, Insights and Forecast - by Virus Type
      • 5.1.1. Genetically engineered oncolytic viruses
        • 5.1.1.1. Adenovirus
        • 5.1.1.2. Herpes simplex virus
        • 5.1.1.3. Vaccinia virus
      • 5.1.2. Oncolytic wild-type viruses
        • 5.1.2.1. Reovirus
        • 5.1.2.2. Vesicular stomatitis virus
        • 5.1.2.3. Newcastle disease virus
    • 5.2. Market Analysis, Insights and Forecast - by Application
      • 5.2.1. Solid tumors
        • 5.2.1.1. Breast cancer
        • 5.2.1.2. Prostate cancer
        • 5.2.1.3. Lung cancer
        • 5.2.1.4. Glioblastoma
      • 5.2.2. Melanoma
        • 5.2.2.1. Leukemia
        • 5.2.2.2. Lymphoma
        • 5.2.2.3. Myeloma
        • 5.2.2.4. Hematological malignancies
    • 5.3. Market Analysis, Insights and Forecast - by End-user
      • 5.3.1. Hospitals
      • 5.3.2. Specialty clinics
      • 5.3.3. Cancer research institutes
    • 5.4. Market Analysis, Insights and Forecast - by Region
      • 5.4.1. North America
      • 5.4.2. Europe
      • 5.4.3. Asia Pacific
      • 5.4.4. Latin America
      • 5.4.5. Middle East and Africa
  6. 6. North America Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 6.1. Market Analysis, Insights and Forecast - by Virus Type
      • 6.1.1. Genetically engineered oncolytic viruses
        • 6.1.1.1. Adenovirus
        • 6.1.1.2. Herpes simplex virus
        • 6.1.1.3. Vaccinia virus
      • 6.1.2. Oncolytic wild-type viruses
        • 6.1.2.1. Reovirus
        • 6.1.2.2. Vesicular stomatitis virus
        • 6.1.2.3. Newcastle disease virus
    • 6.2. Market Analysis, Insights and Forecast - by Application
      • 6.2.1. Solid tumors
        • 6.2.1.1. Breast cancer
        • 6.2.1.2. Prostate cancer
        • 6.2.1.3. Lung cancer
        • 6.2.1.4. Glioblastoma
      • 6.2.2. Melanoma
        • 6.2.2.1. Leukemia
        • 6.2.2.2. Lymphoma
        • 6.2.2.3. Myeloma
        • 6.2.2.4. Hematological malignancies
    • 6.3. Market Analysis, Insights and Forecast - by End-user
      • 6.3.1. Hospitals
      • 6.3.2. Specialty clinics
      • 6.3.3. Cancer research institutes
  7. 7. Europe Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 7.1. Market Analysis, Insights and Forecast - by Virus Type
      • 7.1.1. Genetically engineered oncolytic viruses
        • 7.1.1.1. Adenovirus
        • 7.1.1.2. Herpes simplex virus
        • 7.1.1.3. Vaccinia virus
      • 7.1.2. Oncolytic wild-type viruses
        • 7.1.2.1. Reovirus
        • 7.1.2.2. Vesicular stomatitis virus
        • 7.1.2.3. Newcastle disease virus
    • 7.2. Market Analysis, Insights and Forecast - by Application
      • 7.2.1. Solid tumors
        • 7.2.1.1. Breast cancer
        • 7.2.1.2. Prostate cancer
        • 7.2.1.3. Lung cancer
        • 7.2.1.4. Glioblastoma
      • 7.2.2. Melanoma
        • 7.2.2.1. Leukemia
        • 7.2.2.2. Lymphoma
        • 7.2.2.3. Myeloma
        • 7.2.2.4. Hematological malignancies
    • 7.3. Market Analysis, Insights and Forecast - by End-user
      • 7.3.1. Hospitals
      • 7.3.2. Specialty clinics
      • 7.3.3. Cancer research institutes
  8. 8. Asia Pacific Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 8.1. Market Analysis, Insights and Forecast - by Virus Type
      • 8.1.1. Genetically engineered oncolytic viruses
        • 8.1.1.1. Adenovirus
        • 8.1.1.2. Herpes simplex virus
        • 8.1.1.3. Vaccinia virus
      • 8.1.2. Oncolytic wild-type viruses
        • 8.1.2.1. Reovirus
        • 8.1.2.2. Vesicular stomatitis virus
        • 8.1.2.3. Newcastle disease virus
    • 8.2. Market Analysis, Insights and Forecast - by Application
      • 8.2.1. Solid tumors
        • 8.2.1.1. Breast cancer
        • 8.2.1.2. Prostate cancer
        • 8.2.1.3. Lung cancer
        • 8.2.1.4. Glioblastoma
      • 8.2.2. Melanoma
        • 8.2.2.1. Leukemia
        • 8.2.2.2. Lymphoma
        • 8.2.2.3. Myeloma
        • 8.2.2.4. Hematological malignancies
    • 8.3. Market Analysis, Insights and Forecast - by End-user
      • 8.3.1. Hospitals
      • 8.3.2. Specialty clinics
      • 8.3.3. Cancer research institutes
  9. 9. Latin America Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 9.1. Market Analysis, Insights and Forecast - by Virus Type
      • 9.1.1. Genetically engineered oncolytic viruses
        • 9.1.1.1. Adenovirus
        • 9.1.1.2. Herpes simplex virus
        • 9.1.1.3. Vaccinia virus
      • 9.1.2. Oncolytic wild-type viruses
        • 9.1.2.1. Reovirus
        • 9.1.2.2. Vesicular stomatitis virus
        • 9.1.2.3. Newcastle disease virus
    • 9.2. Market Analysis, Insights and Forecast - by Application
      • 9.2.1. Solid tumors
        • 9.2.1.1. Breast cancer
        • 9.2.1.2. Prostate cancer
        • 9.2.1.3. Lung cancer
        • 9.2.1.4. Glioblastoma
      • 9.2.2. Melanoma
        • 9.2.2.1. Leukemia
        • 9.2.2.2. Lymphoma
        • 9.2.2.3. Myeloma
        • 9.2.2.4. Hematological malignancies
    • 9.3. Market Analysis, Insights and Forecast - by End-user
      • 9.3.1. Hospitals
      • 9.3.2. Specialty clinics
      • 9.3.3. Cancer research institutes
  10. 10. Middle East and Africa Oncolytic Virotherapy Market Analysis, Insights and Forecast, 2019-2031
    • 10.1. Market Analysis, Insights and Forecast - by Virus Type
      • 10.1.1. Genetically engineered oncolytic viruses
        • 10.1.1.1. Adenovirus
        • 10.1.1.2. Herpes simplex virus
        • 10.1.1.3. Vaccinia virus
      • 10.1.2. Oncolytic wild-type viruses
        • 10.1.2.1. Reovirus
        • 10.1.2.2. Vesicular stomatitis virus
        • 10.1.2.3. Newcastle disease virus
    • 10.2. Market Analysis, Insights and Forecast - by Application
      • 10.2.1. Solid tumors
        • 10.2.1.1. Breast cancer
        • 10.2.1.2. Prostate cancer
        • 10.2.1.3. Lung cancer
        • 10.2.1.4. Glioblastoma
      • 10.2.2. Melanoma
        • 10.2.2.1. Leukemia
        • 10.2.2.2. Lymphoma
        • 10.2.2.3. Myeloma
        • 10.2.2.4. Hematological malignancies
    • 10.3. Market Analysis, Insights and Forecast - by End-user
      • 10.3.1. Hospitals
      • 10.3.2. Specialty clinics
      • 10.3.3. Cancer research institutes
  11. 11. Competitive Analysis
    • 11.1. Global Market Share Analysis 2024
      • 11.2. Company Profiles
        • 11.2.1 Amgen Inc.
          • 11.2.1.1. Overview
          • 11.2.1.2. Products
          • 11.2.1.3. SWOT Analysis
          • 11.2.1.4. Recent Developments
          • 11.2.1.5. Financials (Based on Availability)
        • 11.2.2 BioVex Inc.
          • 11.2.2.1. Overview
          • 11.2.2.2. Products
          • 11.2.2.3. SWOT Analysis
          • 11.2.2.4. Recent Developments
          • 11.2.2.5. Financials (Based on Availability)
        • 11.2.3 Circio Holding ASA
          • 11.2.3.1. Overview
          • 11.2.3.2. Products
          • 11.2.3.3. SWOT Analysis
          • 11.2.3.4. Recent Developments
          • 11.2.3.5. Financials (Based on Availability)
        • 11.2.4 Daiichi Sankyo Company
          • 11.2.4.1. Overview
          • 11.2.4.2. Products
          • 11.2.4.3. SWOT Analysis
          • 11.2.4.4. Recent Developments
          • 11.2.4.5. Financials (Based on Availability)
        • 11.2.5 DNAtrix
          • 11.2.5.1. Overview
          • 11.2.5.2. Products
          • 11.2.5.3. SWOT Analysis
          • 11.2.5.4. Recent Developments
          • 11.2.5.5. Financials (Based on Availability)
        • 11.2.6 Lokon Pharma AB
          • 11.2.6.1. Overview
          • 11.2.6.2. Products
          • 11.2.6.3. SWOT Analysis
          • 11.2.6.4. Recent Developments
          • 11.2.6.5. Financials (Based on Availability)
        • 11.2.7 Medigene AG
          • 11.2.7.1. Overview
          • 11.2.7.2. Products
          • 11.2.7.3. SWOT Analysis
          • 11.2.7.4. Recent Developments
          • 11.2.7.5. Financials (Based on Availability)
        • 11.2.8 Oncolytics Biotech Inc.
          • 11.2.8.1. Overview
          • 11.2.8.2. Products
          • 11.2.8.3. SWOT Analysis
          • 11.2.8.4. Recent Developments
          • 11.2.8.5. Financials (Based on Availability)
        • 11.2.9 PsiOxus Therapeutics
          • 11.2.9.1. Overview
          • 11.2.9.2. Products
          • 11.2.9.3. SWOT Analysis
          • 11.2.9.4. Recent Developments
          • 11.2.9.5. Financials (Based on Availability)
        • 11.2.10 Shanghai Sunway Biotech Co. Ltd.
          • 11.2.10.1. Overview
          • 11.2.10.2. Products
          • 11.2.10.3. SWOT Analysis
          • 11.2.10.4. Recent Developments
          • 11.2.10.5. Financials (Based on Availability)
        • 11.2.11 SillaJen Inc.
          • 11.2.11.1. Overview
          • 11.2.11.2. Products
          • 11.2.11.3. SWOT Analysis
          • 11.2.11.4. Recent Developments
          • 11.2.11.5. Financials (Based on Availability)
        • 11.2.12 Sorrento Therapeutics
          • 11.2.12.1. Overview
          • 11.2.12.2. Products
          • 11.2.12.3. SWOT Analysis
          • 11.2.12.4. Recent Developments
          • 11.2.12.5. Financials (Based on Availability)
        • 11.2.13 Theriva Biologics
          • 11.2.13.1. Overview
          • 11.2.13.2. Products
          • 11.2.13.3. SWOT Analysis
          • 11.2.13.4. Recent Developments
          • 11.2.13.5. Financials (Based on Availability)
        • 11.2.14 Transgene SA
          • 11.2.14.1. Overview
          • 11.2.14.2. Products
          • 11.2.14.3. SWOT Analysis
          • 11.2.14.4. Recent Developments
          • 11.2.14.5. Financials (Based on Availability)
        • 11.2.15 Virogin Biotech
          • 11.2.15.1. Overview
          • 11.2.15.2. Products
          • 11.2.15.3. SWOT Analysis
          • 11.2.15.4. Recent Developments
          • 11.2.15.5. Financials (Based on Availability)
List of Figures
  1. Figure 1: Global Oncolytic Virotherapy Market Revenue Breakdown (Million, %) by Region 2024 & 2032
  2. Figure 2: Global Oncolytic Virotherapy Market Volume Breakdown (K Tons, %) by Region 2024 & 2032
  3. Figure 3: North America Oncolytic Virotherapy Market Revenue (Million), by Virus Type 2024 & 2032
  4. Figure 4: North America Oncolytic Virotherapy Market Volume (K Tons), by Virus Type 2024 & 2032
  5. Figure 5: North America Oncolytic Virotherapy Market Revenue Share (%), by Virus Type 2024 & 2032
  6. Figure 6: North America Oncolytic Virotherapy Market Volume Share (%), by Virus Type 2024 & 2032
  7. Figure 7: North America Oncolytic Virotherapy Market Revenue (Million), by Application 2024 & 2032
  8. Figure 8: North America Oncolytic Virotherapy Market Volume (K Tons), by Application 2024 & 2032
  9. Figure 9: North America Oncolytic Virotherapy Market Revenue Share (%), by Application 2024 & 2032
  10. Figure 10: North America Oncolytic Virotherapy Market Volume Share (%), by Application 2024 & 2032
  11. Figure 11: North America Oncolytic Virotherapy Market Revenue (Million), by End-user 2024 & 2032
  12. Figure 12: North America Oncolytic Virotherapy Market Volume (K Tons), by End-user 2024 & 2032
  13. Figure 13: North America Oncolytic Virotherapy Market Revenue Share (%), by End-user 2024 & 2032
  14. Figure 14: North America Oncolytic Virotherapy Market Volume Share (%), by End-user 2024 & 2032
  15. Figure 15: North America Oncolytic Virotherapy Market Revenue (Million), by Country 2024 & 2032
  16. Figure 16: North America Oncolytic Virotherapy Market Volume (K Tons), by Country 2024 & 2032
  17. Figure 17: North America Oncolytic Virotherapy Market Revenue Share (%), by Country 2024 & 2032
  18. Figure 18: North America Oncolytic Virotherapy Market Volume Share (%), by Country 2024 & 2032
  19. Figure 19: Europe Oncolytic Virotherapy Market Revenue (Million), by Virus Type 2024 & 2032
  20. Figure 20: Europe Oncolytic Virotherapy Market Volume (K Tons), by Virus Type 2024 & 2032
  21. Figure 21: Europe Oncolytic Virotherapy Market Revenue Share (%), by Virus Type 2024 & 2032
  22. Figure 22: Europe Oncolytic Virotherapy Market Volume Share (%), by Virus Type 2024 & 2032
  23. Figure 23: Europe Oncolytic Virotherapy Market Revenue (Million), by Application 2024 & 2032
  24. Figure 24: Europe Oncolytic Virotherapy Market Volume (K Tons), by Application 2024 & 2032
  25. Figure 25: Europe Oncolytic Virotherapy Market Revenue Share (%), by Application 2024 & 2032
  26. Figure 26: Europe Oncolytic Virotherapy Market Volume Share (%), by Application 2024 & 2032
  27. Figure 27: Europe Oncolytic Virotherapy Market Revenue (Million), by End-user 2024 & 2032
  28. Figure 28: Europe Oncolytic Virotherapy Market Volume (K Tons), by End-user 2024 & 2032
  29. Figure 29: Europe Oncolytic Virotherapy Market Revenue Share (%), by End-user 2024 & 2032
  30. Figure 30: Europe Oncolytic Virotherapy Market Volume Share (%), by End-user 2024 & 2032
  31. Figure 31: Europe Oncolytic Virotherapy Market Revenue (Million), by Country 2024 & 2032
  32. Figure 32: Europe Oncolytic Virotherapy Market Volume (K Tons), by Country 2024 & 2032
  33. Figure 33: Europe Oncolytic Virotherapy Market Revenue Share (%), by Country 2024 & 2032
  34. Figure 34: Europe Oncolytic Virotherapy Market Volume Share (%), by Country 2024 & 2032
  35. Figure 35: Asia Pacific Oncolytic Virotherapy Market Revenue (Million), by Virus Type 2024 & 2032
  36. Figure 36: Asia Pacific Oncolytic Virotherapy Market Volume (K Tons), by Virus Type 2024 & 2032
  37. Figure 37: Asia Pacific Oncolytic Virotherapy Market Revenue Share (%), by Virus Type 2024 & 2032
  38. Figure 38: Asia Pacific Oncolytic Virotherapy Market Volume Share (%), by Virus Type 2024 & 2032
  39. Figure 39: Asia Pacific Oncolytic Virotherapy Market Revenue (Million), by Application 2024 & 2032
  40. Figure 40: Asia Pacific Oncolytic Virotherapy Market Volume (K Tons), by Application 2024 & 2032
  41. Figure 41: Asia Pacific Oncolytic Virotherapy Market Revenue Share (%), by Application 2024 & 2032
  42. Figure 42: Asia Pacific Oncolytic Virotherapy Market Volume Share (%), by Application 2024 & 2032
  43. Figure 43: Asia Pacific Oncolytic Virotherapy Market Revenue (Million), by End-user 2024 & 2032
  44. Figure 44: Asia Pacific Oncolytic Virotherapy Market Volume (K Tons), by End-user 2024 & 2032
  45. Figure 45: Asia Pacific Oncolytic Virotherapy Market Revenue Share (%), by End-user 2024 & 2032
  46. Figure 46: Asia Pacific Oncolytic Virotherapy Market Volume Share (%), by End-user 2024 & 2032
  47. Figure 47: Asia Pacific Oncolytic Virotherapy Market Revenue (Million), by Country 2024 & 2032
  48. Figure 48: Asia Pacific Oncolytic Virotherapy Market Volume (K Tons), by Country 2024 & 2032
  49. Figure 49: Asia Pacific Oncolytic Virotherapy Market Revenue Share (%), by Country 2024 & 2032
  50. Figure 50: Asia Pacific Oncolytic Virotherapy Market Volume Share (%), by Country 2024 & 2032
  51. Figure 51: Latin America Oncolytic Virotherapy Market Revenue (Million), by Virus Type 2024 & 2032
  52. Figure 52: Latin America Oncolytic Virotherapy Market Volume (K Tons), by Virus Type 2024 & 2032
  53. Figure 53: Latin America Oncolytic Virotherapy Market Revenue Share (%), by Virus Type 2024 & 2032
  54. Figure 54: Latin America Oncolytic Virotherapy Market Volume Share (%), by Virus Type 2024 & 2032
  55. Figure 55: Latin America Oncolytic Virotherapy Market Revenue (Million), by Application 2024 & 2032
  56. Figure 56: Latin America Oncolytic Virotherapy Market Volume (K Tons), by Application 2024 & 2032
  57. Figure 57: Latin America Oncolytic Virotherapy Market Revenue Share (%), by Application 2024 & 2032
  58. Figure 58: Latin America Oncolytic Virotherapy Market Volume Share (%), by Application 2024 & 2032
  59. Figure 59: Latin America Oncolytic Virotherapy Market Revenue (Million), by End-user 2024 & 2032
  60. Figure 60: Latin America Oncolytic Virotherapy Market Volume (K Tons), by End-user 2024 & 2032
  61. Figure 61: Latin America Oncolytic Virotherapy Market Revenue Share (%), by End-user 2024 & 2032
  62. Figure 62: Latin America Oncolytic Virotherapy Market Volume Share (%), by End-user 2024 & 2032
  63. Figure 63: Latin America Oncolytic Virotherapy Market Revenue (Million), by Country 2024 & 2032
  64. Figure 64: Latin America Oncolytic Virotherapy Market Volume (K Tons), by Country 2024 & 2032
  65. Figure 65: Latin America Oncolytic Virotherapy Market Revenue Share (%), by Country 2024 & 2032
  66. Figure 66: Latin America Oncolytic Virotherapy Market Volume Share (%), by Country 2024 & 2032
  67. Figure 67: Middle East and Africa Oncolytic Virotherapy Market Revenue (Million), by Virus Type 2024 & 2032
  68. Figure 68: Middle East and Africa Oncolytic Virotherapy Market Volume (K Tons), by Virus Type 2024 & 2032
  69. Figure 69: Middle East and Africa Oncolytic Virotherapy Market Revenue Share (%), by Virus Type 2024 & 2032
  70. Figure 70: Middle East and Africa Oncolytic Virotherapy Market Volume Share (%), by Virus Type 2024 & 2032
  71. Figure 71: Middle East and Africa Oncolytic Virotherapy Market Revenue (Million), by Application 2024 & 2032
  72. Figure 72: Middle East and Africa Oncolytic Virotherapy Market Volume (K Tons), by Application 2024 & 2032
  73. Figure 73: Middle East and Africa Oncolytic Virotherapy Market Revenue Share (%), by Application 2024 & 2032
  74. Figure 74: Middle East and Africa Oncolytic Virotherapy Market Volume Share (%), by Application 2024 & 2032
  75. Figure 75: Middle East and Africa Oncolytic Virotherapy Market Revenue (Million), by End-user 2024 & 2032
  76. Figure 76: Middle East and Africa Oncolytic Virotherapy Market Volume (K Tons), by End-user 2024 & 2032
  77. Figure 77: Middle East and Africa Oncolytic Virotherapy Market Revenue Share (%), by End-user 2024 & 2032
  78. Figure 78: Middle East and Africa Oncolytic Virotherapy Market Volume Share (%), by End-user 2024 & 2032
  79. Figure 79: Middle East and Africa Oncolytic Virotherapy Market Revenue (Million), by Country 2024 & 2032
  80. Figure 80: Middle East and Africa Oncolytic Virotherapy Market Volume (K Tons), by Country 2024 & 2032
  81. Figure 81: Middle East and Africa Oncolytic Virotherapy Market Revenue Share (%), by Country 2024 & 2032
  82. Figure 82: Middle East and Africa Oncolytic Virotherapy Market Volume Share (%), by Country 2024 & 2032
List of Tables
  1. Table 1: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Region 2019 & 2032
  2. Table 2: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Region 2019 & 2032
  3. Table 3: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  4. Table 4: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  5. Table 5: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  6. Table 6: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  7. Table 7: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  8. Table 8: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  9. Table 9: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Region 2019 & 2032
  10. Table 10: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Region 2019 & 2032
  11. Table 11: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  12. Table 12: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  13. Table 13: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  14. Table 14: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  15. Table 15: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  16. Table 16: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  17. Table 17: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Country 2019 & 2032
  18. Table 18: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Country 2019 & 2032
  19. Table 19: U.S. Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  20. Table 20: U.S. Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  21. Table 21: Canada Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  22. Table 22: Canada Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  23. Table 23: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  24. Table 24: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  25. Table 25: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  26. Table 26: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  27. Table 27: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  28. Table 28: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  29. Table 29: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Country 2019 & 2032
  30. Table 30: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Country 2019 & 2032
  31. Table 31: Germany Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  32. Table 32: Germany Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  33. Table 33: UK Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  34. Table 34: UK Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  35. Table 35: France Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  36. Table 36: France Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  37. Table 37: Spain Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  38. Table 38: Spain Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  39. Table 39: Italy Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  40. Table 40: Italy Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  41. Table 41: Netherlands Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  42. Table 42: Netherlands Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  43. Table 43: Rest of Europe Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  44. Table 44: Rest of Europe Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  45. Table 45: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  46. Table 46: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  47. Table 47: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  48. Table 48: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  49. Table 49: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  50. Table 50: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  51. Table 51: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Country 2019 & 2032
  52. Table 52: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Country 2019 & 2032
  53. Table 53: China Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  54. Table 54: China Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  55. Table 55: Japan Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  56. Table 56: Japan Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  57. Table 57: India Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  58. Table 58: India Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  59. Table 59: Australia Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  60. Table 60: Australia Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  61. Table 61: South Korea Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  62. Table 62: South Korea Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  63. Table 63: Rest of Asia Pacific Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  64. Table 64: Rest of Asia Pacific Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  65. Table 65: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  66. Table 66: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  67. Table 67: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  68. Table 68: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  69. Table 69: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  70. Table 70: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  71. Table 71: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Country 2019 & 2032
  72. Table 72: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Country 2019 & 2032
  73. Table 73: Brazil Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  74. Table 74: Brazil Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  75. Table 75: Mexico Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  76. Table 76: Mexico Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  77. Table 77: Rest of Latin America Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  78. Table 78: Rest of Latin America Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  79. Table 79: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Virus Type 2019 & 2032
  80. Table 80: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Virus Type 2019 & 2032
  81. Table 81: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Application 2019 & 2032
  82. Table 82: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Application 2019 & 2032
  83. Table 83: Global Oncolytic Virotherapy Market Revenue Million Forecast, by End-user 2019 & 2032
  84. Table 84: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by End-user 2019 & 2032
  85. Table 85: Global Oncolytic Virotherapy Market Revenue Million Forecast, by Country 2019 & 2032
  86. Table 86: Global Oncolytic Virotherapy Market Volume K Tons Forecast, by Country 2019 & 2032
  87. Table 87: South Africa Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  88. Table 88: South Africa Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  89. Table 89: Saudi Arabia Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  90. Table 90: Saudi Arabia Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  91. Table 91: UAE Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  92. Table 92: UAE Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032
  93. Table 93: Rest of Middle East and Africa Oncolytic Virotherapy Market Revenue (Million) Forecast, by Application 2019 & 2032
  94. Table 94: Rest of Middle East and Africa Oncolytic Virotherapy Market Volume (K Tons) Forecast, by Application 2019 & 2032

STEP 1 - Identification of Relevant Samples Size from Population Database

Step Chart
bar chart
method chart

STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

approach chart
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.

Note* : In applicable scenarios

STEP 3 - Data Sources

Primary Research

  • Web Analytics
  • Survey Reports
  • Research Institute
  • Latest Research Reports
  • Opinion Leaders

Secondary Research

  • Annual Reports
  • White Paper
  • Latest Press Release
  • Industry Association
  • Paid Database
  • Investor Presentations
approach chart

STEP 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.

Frequently Asked Questions

Related Reports

See the similar reports

Discover the Latest Market Insight Reports

Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.

shop image 1

About Market Insights Report

Market Insights Reports offers comprehensive market research reports and analysis, giving businesses important information about their clients, rivals, and sector to help them make well-informed decisions on operations, marketing, and business strategy. We offer a variety of services in addition to market research, data analysis, and strategy planning. In order to find opportunities and learn more about our competitors and the industry at large, we employ competitive analysis. To identify areas for development, we also evaluate our performance against that of our rivals. We can determine the places at which we can offer our clients the most value by performing value chain analysis.

Additionally, clients receive a thorough overview of their industry business environment. We can find trends that help us forecast future possibilities and threats by examining global macroeconomic dynamics and consumer behavior patterns. By analyzing their features and advantages, contrasting them with comparable items on the market, and evaluating both their quantitative and qualitative performance, we comprehensively evaluate our clients' products. This allows us to assist customers in determining how their goods compare to those of their rivals and in creating successful marketing plans. Our group has been successful in gaining a thorough grasp of our clients' requirements and offering them creative solutions. We currently provide services to more than 50 nations in Europe, the Middle East, Africa, Latin America, Asia Pacific, and North America. Because of our global reach, we have been able to establish trusting bonds with our partners and clients in various nations, improving customer service and forging a more cohesive worldwide presence.

We use cookies to enhance your experience.

By clicking "Accept All", you consent to the use of all cookies.

Customize your preferences or read our Cookie Policy.